Please use this identifier to cite or link to this item:
|Title:||Favipiravir in early symptomatic COVID-19, a randomised placebo-controlled trial.||Austin Authors:||McMahon, James H;Lau, Jillian S Y;Coldham, Anna;Roney, Janine;Hagenauer, Michelle;Price, Sally;Bryant, Mellissa;Garlick, Jill;Paterson, Anne;Lee, Sue J;O'Bryan, Jess;Hearps, Anna;Tachedjian, Gilda;Pinskier, Henry;Phillips, Cameron;Garrow, Stuart;Pinskier, Nathan;Melvin, Robert;Blakeway, Luke;Wisniewski, Jessica A;Byers, Sally;Badoordeen, Gnei Z;Pereira, Stephanie;Pragastis, Katherine;Trubiano, Jason ;Chua, Kyra Y L ;Kainer, Marion;Molton, James S;Gardiner, Bradley J;Pierce, Anna B;Cheng, Allen;Rogers, Benjamin A;Peleg, Anton Y||Affiliation:||Department of Infectious Diseases, Alfred Hospital and Central Clinical School, Monash University, Melbourne, Australia.
Department of Infectious Diseases, Monash Medical Centre, Melbourne, Australia.
Life Sciences Discipline, Burnet Institute, Melbourne, Australia.
Onsite Doctor and OSD.Care, Melbourne, Australia.
Department of Emergency Medicine, Alfred Hospital, Melbourne, Australia.
Department of Infectious Diseases, Alfred Hospital and Central Clinical School, Monash University, Melbourne, Australia.
Department of Infectious Diseases, Western Health, Melbourne, Australia.
|Issue Date:||Dec-2022||Date:||2022||Publication information:||EClinicalMedicine 2022; 54||Abstract:||Well tolerated antivirals administered early in the course of COVID-19 infection when the viremia is highest could prevent progression to severe disease. Favipiravir inhibits SARS-CoV-2 viral replication in vitro with evidence of clinical benefit in open label trials. Placebo controlled studies of people with early symptomatic COVID-19 with regular assessments of SARS-CoV-2 viral load can determine if it has an antiviral effect and improves clinical outcomes.||URI:||https://ahro.austin.org.au/austinjspui/handle/1/31621||DOI:||10.1016/j.eclinm.2022.101703||ORCID:||Journal:||EClinicalMedicine||Start page:||101703||PubMed URL:||36284645||ISSN:||2589-5370||Type:||Journal Article||Subjects:||COVID-19
Randomised clinical trial
|Appears in Collections:||Journal articles|
Show full item record
checked on Sep 29, 2023
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.